Overview

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
0
Participant gender:
All
Summary
Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Central Institute of Mental Health, Mannheim
Collaborator:
Max-Planck Institute for Metabolism Research
Treatments:
Cannabidiol
Insulin
Insulin, Globin Zinc
Criteria
Inclusion Criteria:

- Healthy volunteers

- Informed consent given by the subject

- Both, female and male subjects may participate

- Age between 18 and 65 years

- Negative drug-screening at the time of screening

- In female participants in fertile age, reliable contraception, which means
contraception's pearl-index is equal or smaller than 1.

- Non-Smoker

- Body Mass Index between 18 and 40.

Exclusion Criteria:

- Lack of accountability

- Any current psychiatric disorder through the Structured Clinical Interview for DSM-IV
(SCID) at the time of screening

- Any known psychiatric or neurological illness in the participant's history.

- Known family history concerning psychiatric disorders

- Relevant use of cannabis (which is defined on the present state of knowledge as at the
most five times lifetime-consumption and no consumption for at least one year)

- Pregnancy or lactation phase in female at the time of screening

- Severe physical (internal) or neurological illness, especially cardiovascular, renal,
advanced respiratory, haematological or endocrinological failures or infectious
diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by
the subject's history, clinical examination and laboratory testing, at the discretion
of the investigator

- Consumption of any illegal drugs (except cannabis in history, see above)